Biopharmaceutical Company Arsanis, Inc. (ASNS) announced Thursday the discontinuation of its Phase 2 clinical trial of ASN100 for the prevention of S. aureus pneumonia in high-risk, mechanically ventilated patients. The move follows the completion of a planned interim analysis of unblinded trial data by an independent data review committee (DRC).
from RTT - Biotech https://ift.tt/2yLz5ma
via IFTTT
No comments:
Post a Comment